Genetics of Parkinson's Disease: Lysosomal Dysfunction Antibody Sampler Kit #78646
Product Information
Kit Usage Information
Protocols
- 5879: Western Blotting, Immunoprecipitation (Magnetic)
- 7074: Western Blotting
- 13046: Western Blotting, Immunoprecipitation (Agarose)
- 51510: Western Blotting, Immunoprecipitation (Magnetic), Immunohistochemistry (Paraffin), Immunofluorescence, Immunofluorescence
- 74089: Western Blotting, Immunohistochemistry (Paraffin), IF-F Citrate Retrieval (Rabbit), Immunofluorescence*
- 81453: Western Blotting, Immunoprecipitation (Agarose)
- 88162: Western Blotting
Product Description
The Genetics of Parkinson's Disease: Lysosomal Dysfunction Antibody Sampler Kit provides an economical means of investigating lysosomal proteins that are commonly mutated in Parkinson’s disease (PD) by western blot. The kit includes enough antibodies to perform two western blot experiments with each primary antibody.
Background
The antibodies in this kit serve to characterize genes implicated in Parkinson’s disease (PD) that lead to lysosomal dysfunction. The cellular function of lysosomes is to degrade and recycle cellular waste, maintaining proper cellular energy metabolism. GBA mutations are the most common genetic risk factor for PD, a neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra with formation of Lewy bodies in surviving neurons (1,2). In the absence of GBA, which encodes β-glucocerebrosidase (GCase), autophagic lysosome reformation is altered, suggesting that GCase activity is critical to maintaining functional lysosomes. GCase catalyzes the hydrolysis of glucocerebroside into free ceramide and glucose (3). Lysosomal breakdown of glucocerebroside is required for complex lipid cellular metabolism and proper cellular membrane turnover (4).
α-Synuclein (α-Syn) is the main component of pathogenic Lewy bodies and neurites. Research studies have shown that mutations in the α-Synuclein gene are linked to PD (5). Neuronally generated pathogenic species of α-Syn accumulate within neuronal lysosomes and are released via SNARE-dependent lysosomal exocytosis. The released aggregates are non-membrane enveloped and seeding-competent, further contributing to PD pathology (6).
PARK9, also known as ATP13A2, is a member of the P-type ATPase superfamily. It localizes to the lysosomal membrane and is involved in the lysosomal degradation pathway, clearing α-Syn aggregates (7,8).
Cathepsin D (CTSD) is a ubiquitously expressed lysosomal aspartyl protease involved in normal protein degradation. Loss of CTSD leads to lysosomal dysfunction and accumulation of different cellular proteins implicated in neurodegenerative diseases, such as α-Syn (9).
Another gene genetically linked to PD is leucine-rich repeat kinase 2 (LRRK2), also known as PARK8 (10). Research studies have linked at least 20 mutations in LRRK2 to PD, with the G2019S mutation being the most prevalent (11). LRRK2 mutations alter lysosome morphology, distribution, pH, and degradative capacity in many distinct cell types, including fibroblasts, striatal neurons, primary neurons, and primary astrocytes (12).
Mutations in the vacuolar protein sorting-associated protein 35 (VPS35) gene, encoding a core component of the retromer complex, have recently emerged as a new cause of late-onset, autosomal dominant familial PD. A single missense mutation, Asp620Asn (D620N), has so far been unambiguously identified to cause PD (13). The VPS35 D620N mutation alters the expression of ~220 lysosomal proteins and stimulates recruitment of LRRK2 and phosphorylation of Rab proteins at the lysosome (14).
α-Synuclein (α-Syn) is the main component of pathogenic Lewy bodies and neurites. Research studies have shown that mutations in the α-Synuclein gene are linked to PD (5). Neuronally generated pathogenic species of α-Syn accumulate within neuronal lysosomes and are released via SNARE-dependent lysosomal exocytosis. The released aggregates are non-membrane enveloped and seeding-competent, further contributing to PD pathology (6).
PARK9, also known as ATP13A2, is a member of the P-type ATPase superfamily. It localizes to the lysosomal membrane and is involved in the lysosomal degradation pathway, clearing α-Syn aggregates (7,8).
Cathepsin D (CTSD) is a ubiquitously expressed lysosomal aspartyl protease involved in normal protein degradation. Loss of CTSD leads to lysosomal dysfunction and accumulation of different cellular proteins implicated in neurodegenerative diseases, such as α-Syn (9).
Another gene genetically linked to PD is leucine-rich repeat kinase 2 (LRRK2), also known as PARK8 (10). Research studies have linked at least 20 mutations in LRRK2 to PD, with the G2019S mutation being the most prevalent (11). LRRK2 mutations alter lysosome morphology, distribution, pH, and degradative capacity in many distinct cell types, including fibroblasts, striatal neurons, primary neurons, and primary astrocytes (12).
Mutations in the vacuolar protein sorting-associated protein 35 (VPS35) gene, encoding a core component of the retromer complex, have recently emerged as a new cause of late-onset, autosomal dominant familial PD. A single missense mutation, Asp620Asn (D620N), has so far been unambiguously identified to cause PD (13). The VPS35 D620N mutation alters the expression of ~220 lysosomal proteins and stimulates recruitment of LRRK2 and phosphorylation of Rab proteins at the lysosome (14).
- Sidransky, E. and Lopez, G. (2012) Lancet Neurol 11, 986-98.
- Neumann, J. et al. (2009) Brain 132, 1783-94.
- Ho, M.W. et al. (1973) Biochem J 131, 173-6.
- Magalhaes, J. et al. (2016) Hum Mol Genet 25, 3432-3445.
- Goldberg, M.S. and Lansbury, P.T. (2000) Nat Cell Biol 2, E115-9.
- Xie, Y.X. et al. (2022) Nat Commun 13, 4918.
- Ramirez, A. et al. (2006) Nat Genet 38, 1184-91.
- Xiromerisiou, G. et al. (2010) Neurosurg Focus 28, E7.
- Faust, P.L. et al. (1985) Proc Natl Acad Sci USA 82, 4910-4.
- Moore, D.J. et al. (2005) Annu Rev Neurosci 28, 57-87.
- Mata, I.F. et al. (2006) Trends Neurosci 29, 286-93.
- Erb, M.L. and Moore, D.J. (2020) J Parkinsons Dis 10, 1271-1291.
- Williams, E.T. et al. (2017) J Parkinsons Dis 7, 219-233.
- Pal, P. et al. (2023) Sci Adv 9, eadj1205.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意,否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件,除非书 CST 的合法授书代表以书面形式书独接受, 否书均被拒书,并且无效。
专品专有“专供研究使用”的专专或专似的专专声明, 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的, 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专,且专用于研专用途。将专品用于专断、专防或治专目的, 或专专售(专独或作专专成)或其他商专目的而专专专品,均需要 CST 的专独专可。客专:(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品,或使用专品制造任何商专专品,(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专,或使用专品开专任何与 CST 的专品或服专专争的专品或服专, (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专,(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品, (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.